From: Effectiveness and safety of KunXian capsule for the treatment of IgA nephropathy
Characteristic | n = 32 | Remissions n = 23 | P-value |
---|---|---|---|
Age (years) | 39.5 ± 8.2 | 36.9 ± 7.7 | 0.24 |
Female sex, n (%) | 23 (71.9%) | 8 (34.8%) | 0.01 |
Diabetes mellitus | 4 (12.5%) | 0 (0.0%) | 0.22 |
Previous immunosuppressantsa | 28 (87.5%) | 20 (87.0%) | 1.0 |
Receiving immunosuppressants at baselinea | 23 (71.9%) | 13 (56.5%) | 0.37 |
Receiving TW at baselinea | 16 (50.0%) | 4 (17.4%) | 0.03 |
Receiving RASi at baseline | 27 (84.4%) | 23 (100.0%) | 0.13 |
Proteinuria (g/24 h) | 2.4 (1.9, 3.5) | 1.8 (1.5, 2.3) | 0.01 |
Mean artery pressure at baseline (mmHg) | 96.8 ± 11.0 | 91.0 ± 9.2 | 0.05 |
estimated GFR (ml/min per 1.73 m2) | 63 ± 13 | 68 ± 11 | 0.14 |
eGFR < 60 ml/min per 1.73 m2 | 15 (46.9) | 6 (26.1) | 0.20 |
Serum albumin (g/dl) | 39.6 (3.5) | 41.7 (3.3) | 0.03 |
KuXian Dosage (ug) | 102 ± 24 | 100 ± 26 | 0.71 |